IMF Videos Search Content For Healthcare Professional (70) Healthcare Provider (70) Series - Any - About the IMF (2) ASCO/EHA (70) ASH (102) Ask Dr. Durie (150) Black Swan Research Initiative (7) Community Workshops (5) Emerging Therapies (18) Facebook Live (21) Health Equity (14) IMF History (3) IMWG (12) Inspirational (15) Living Well with Myeloma (33) Myeloma in a Minute (20) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (11) Q&A (21) Recent News and Developments (5) Treatments (3) Trending Searches in Myeloma (4) Topics Clinical Trials (49) Financial Considerations (1) Frontline Therapy (16) Health Equity (2) Lab & Imaging Tests (1) Mental & Emotional Health (1) Myeloma in the News (1) Public Policy & Advocacy (1) Recorded Webinars (2) Relapse/Refractory Myeloma (31) Research Updates (51) Symptom Management (4) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (16) High-Risk Myeloma (14) High-risk Smoldering Myeloma (9) Late Relapse (4–6 Lines of Therapy) (29) MGUS (5) Newly Diagnosed (Pre-Treatment or First Treatment) (20) Smoldering Myeloma (7) Types of Therapy Immunomodulatory drugs (IMiDs) (22) Immunotherapies (CAR T; BiTE, etc.) (30) Monoclonal antibodies (20) Proteasome inhibitors (20) Stem cell transplant (10) Steroids (17) Supportive Care (8) Year Published 2026 (1) 2025 (14) 2024 (17) 2023 (17) 2022 (1) 2021 (3) 2020 (3) 2019 (2) 2018 (2) 2017 (5) 2015 (5) Trusted Voices Dr. Joseph Mikhael (2) Dr. María-Victoria Mateos (1) Dr. S. Vincent Rajkumar (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Elranatamab in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: MagnetisMM-6 June 27, 2025 ASCO/EHA CAR-T Therapy in RR AL Amyloidosis: NEXICART-2 Trial Safety and Efficacy June 23, 2025 ASCO/EHA First-in-human JNJ-79635322 trispecific antibody study in RRMM patients: Initial phase 1 results June 19, 2025 ASCO/EHA Key Multiple Myeloma Abstracts Presented at 2024 ASCO and EHA Meeting August 1, 2024 ASCO/EHA Evaluation of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma and prior anti-CD38–directed therapy: MagnetisMM-32 July 31, 2024 ASCO/EHA MagnetisMM-30, a Phase 1b Study of ELRA and IBER Combination in Relapsed Refractory Multiple Myeloma July 15, 2024 ASCO/EHA DREAMM-7: Belamaf+BVd vs DVd in RRMM, subgroup analyses of phase 3 trial comparing regimens after relapse July 12, 2024 ASCO/EHA Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Newly-Diagnosed Multiple Myeloma: GMMG-HD7 Interim Analysis June 28, 2024 ASCO/EHA Phase I Study: Dual Targeting BCMA & CD19 FASTCAR-T for High-Risk Multiple Myeloma June 27, 2024 ASCO/EHA Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Newly-Diagnosed Multiple Myeloma: GMMG-HD7 Interim Analysis June 24, 2024 ASCO/EHA Class comparison of BCMA-directed therapies in relapsed multiple myeloma June 24, 2024 ASCO/EHA MajesTEC-1: Longer Follow-up Teclistamab + Tocilizumab Prophylaxis for CRS in Relapsed/Refractory Myeloma June 21, 2024 ASCO/EHA Load More
